Digital Therapeutics (DTx): How Are These Solutions Evolving in Spain in 2025?
Digital Therapeutics (DTx) continue to experience exponential growth, emerging as innovative solutions that are transforming how we prevent, manage, and treat a wide range of diseases and conditions. Over the past three years, investment in DTx companies has reached an estimated EUR 1 billion, a 92% increase compared with the cumulative total of the previous six years.
Persei vivarium renews its B Corp certification, reaffirming its commitment to a positive impact on health and people
Persei vivarium, which first obtained B Corp Certification in 2022, has successfully completed its recertification process, a rigorous evaluation carried out every three years to ensure continuous improvement and alignment between purpose, practices, and social and environmental impact results.
Persei vivarium among the “World’s Top HealthTech Companies” of 2025
Persei vivarium has been included in the ranking of the “World’s Top HealthTech Companies 2025”, a global reference publication that recognizes the most influential businesses in the world in the field of health technology. The list was developed by the well-known TIME magazine, in collaboration with the data analysis firm Statista.
Persei vivarium boosts its growth by joining Zelenza Group
Persei vivarium is joining Zelenza, a leading Spanish technology group in Managed Services, Engineering, and Security, forging an alliance that will enhance the development of our company and enable Zelenza’s access to the healthcare sector, where Persei vivarium is positioned as a pioneer in Digital Health.
Persei vivarium renews their ISO 27001 certificate, adapting to the latest version of the international standard
Our business, Persei vivarium, has successfully passed the audit for recertification of the ISO/IEC 27001, the international benchmark standard for management of information security. This time, the renewal involved an additional focus, incorporating the changes to the latest version of the standard.
Interview with Enrique Conde, CEO of the CRO Effice Research, on the future of Clinical Research
Interview with Enrique Conde, CEO of Effice Research, on the future of clinical research.
Effice Research is a Contract Research Organization (CRO) that collaborates with our company, Persei vivarium, on research projects.